Monday, November 06, 2006

AMG 706: not so hot

According to a Merrill Lynch analyst, AMG 706 appears to be neither as safe or as efficacious as Sutent. The key data in his conclusion: 3% patient response for AMG 706 vs. 7% response in P3 Sutent trials.

One thing to keep in mind: all trials data relates to GIST, which is probably not the target market for AMG 706 (or Sutent, for that matter.)

No comments: